Pharma BD Deal Intelligence
Criticized as overpriced but eventually enabled AstraZeneca biologics transformation
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
This acquisition represents a transformational step to deliver our biologics strategy sooner than anticipated. It creates a leading fully integrated biologics…
AstraZeneca to buy MedImmune for $15.6 billion.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
AstraZeneca acquired MedImmune for approximately $15.6 billion ($58 per share in cash), gaining a leading biologics and vaccines platform including blockbuster Synagis, FluMist, and a 45-project pipeline to transform AstraZeneca into an integrated biologics company.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / MedImmune Inc. (this deal) | 2007 | $15.6B | 82 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / CinCor Pharma Inc. | 2023 | $1.8B | 78 |
← Browse all deals · How we score deals
More: 2007 deals · AstraZeneca PLC deals · Infectious Disease deals